Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-881 (Takeda)
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
TAK-881 is a 20% concentration formulation of subcutaneous immune globulin (SCIG) developed by Takeda for the treatment of primary immunodeficiency diseases (PIDD). It is designed to be administered as part of a facilitated subcutaneous immunoglobulin (fSCIG) system, where it is co-administered with recombinant human hyaluronidase (rHuPH20). This 20% formulation is a higher-concentration successor to the 10% immune globulin component of Hyqvia (TAK-771), intended to reduce infusion volumes and potentially shorten administration times while maintaining the extended dosing interval (every 3 to 4 weeks) typical of facilitated delivery. By providing a broad spectrum of opsonizing and neutralizing IgG antibodies, TAK-881 serves as a replacement therapy to restore passive immunity in patients with antibody deficiencies.
- Other names
- Immune Globulin Subcutaneous (Human) 20% Solution20% IGSC20% fIGSC (component)
02
Targets
NeuraminidaseFCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on TAK-881 (Takeda).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-881 (Takeda).